Paragon 28

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Paragon 28 reports strong revenue growth and strategic initiatives outlook

Paragon 28 delivered robust financial results in Q4 2022 and full-year 2022, driven by strong revenue growth in the U.S. and international markets.
While facing challenges in achieving profitability and commercializing new technologies, the company's focus on innovation and market expansion presents opportunities for future growth.
With a solid liquidity position and strategic initiatives in place, Paragon 28 is well-positioned to capitalize on market opportunities and drive continued performance.
Investors can look forward to the company's projected revenue growth in 2023 and advancements in technology adoption for improved patient outcomes.

Paragon 28 reports record Q1 revenue, eyes global growth opportunities

Paragon 28 delivered robust financial performance in Q1 2023, driven by strong revenue growth in the U.S. and internationally. While challenges in achieving profitability persist, the company's strategic focus on product development and global market expansion positions it for continued success. Opportunities for growth include optimizing sales force efficiency, launching new products, and capitalizing on international market strength.

Paragon 28 reports strong Q2 performance, eyes international expansion

Paragon 28's Q2 2023 earnings call reflects robust financial performance, driven by international growth and successful product launches.
While facing supply chain challenges and anticipating a growth slowdown, the company remains focused on expanding its market reach and product offerings.
Investments in key markets and a strategic focus on emerging growth drivers underscore Paragon 28's commitment to sustained revenue growth.
Prudence in guidance and operational planning amidst uncertainties highlights the company's proactive approach to managing challenges and seizing opportunities.

Paragon 28 reports steady Q3 growth amidst supply chain challenges

Paragon 28's Q3 2023 earnings call highlighted steady revenue growth, product innovation, and strategic investments driving performance.
While facing supply chain challenges and billing day impacts, the company's focus on market-specific strategies and surgeon training remains a strength.
Securing a new credit facility and reaffirming revenue guidance underscore Paragon 28's commitment to future growth and market leadership.

Paragon 28 reports robust Q4 performance, eyes growth in 2024

Paragon 28's strong performance in Q4 2023, coupled with expectations for growth in 2024, positions the company well for the future. Despite challenges like supply chain issues, the company's focus on innovation and market expansion presents significant opportunities. By maintaining accountability and leveraging market opportunities, Paragon 28 aims to drive continued success.

Paragon 28 reports record Q1 revenue, eyes growth opportunities

Paragon 28's Q1 2024 performance reflects strong revenue growth and strategic product launches.
While facing challenges like negative cash flow and increased SG&A expenses, the company remains optimistic.
Opportunities lie in upcoming product launches, market expansion, and engagement with investors.
Overall, Paragon 28's resilience and growth trajectory position it well for future success in the medical devices sector.

Paragon 28 reports record revenue and positive EBITDA in Q3

Paragon 28's Q3 2024 performance reflects strong revenue growth, product innovation, and a milestone in positive adjusted EBITDA post-IPO.
The company's emphasis on operational efficiency and cost optimization positions it well for sustained profitability and growth.
While facing challenges in cash flow and margin stabilization, Paragon 28 has opportunities to capitalize on its strengths and drive further expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced its new nationwide mobile training lab tour, for convenient, on-site surgeon training and education. Paragon 28's new mobile lab is housed in a 43x30 foot tractor-trailer which includes a state-of-the-art, 6-station, cadaveric training facility accommodating up to 20 surgeons. The mobile lab will host over 50 training sess

Paragon 28 Launches Mobile Medical Education Lab Tour, Expanding Opportunities for Foot and Ankle Surgeon Education

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the launch of its Monkey Rings™ Circular External Fixation System for trauma, deformity correction, and limb salvage. The Monkey Rings Circular External Fixation System is designed to use external wires and screws that can be fixed into bone to maintain anatomic position while providing stability, preservation of soft tiss

Paragon 28 Launches Monkey Rings™ Circular External Fixation System

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The TenoTac™ 2.0 Soft Tissue Fixation System uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surfa

Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-tissue portfolio with the launch of its Grappler™ Suture Anchor System. The Grappler™ Suture Anchor System provides surgeons an alternative fixation option designed to limit implant migration and loss of tension for intraoperative tissue reattachment and fixation in the foot and ankle. “We are exci

Paragon 28 Expands Soft Tissue Portfolio with Grappler™ Suture Anchor System Launch

Paragon 28, Inc. (NYSE:FNA ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Matt Bacso - Gilmartin Group Albert DaCosta - Co Founder, President and Chief Executive Officer Stephen Deitsch - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler David Turkaly - JMP Securities Mike Mattson - Needham & Company Operator Good afternoon and welcome to the Paragon 28's First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Paragon 28, Inc. (FNA) CEO Albert DaCosta on Q1 2022 Results - Earnings Call Transcript

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended March 31, 2022 and updated its 2022 revenue guidance. Financial Highlights Net revenue $41.4 million for the first quarter of 2022, representing growth of 25% over the first quarter of 2021 U.S. revenue for the first quarter of 2022 was $36.0 million, representing growth o

Paragon 28 Reports First Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its hammertoe and soft-tissue portfolio with the launch of its Paratrooper™ Plantar Plate Repair System. The Paratrooper™ Plantar Plate System's low profile, all-suture implant provides surgeons a new and innovative approach for plantar plate repair and forefoot deformities. Paragon 28's CEO, Albert DaCosta

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the launch of its R3ACT™ Stabilization System, designed to be a simple solution that allows for multi-stage soft tissue healing following an acute or chronic syndesmotic injury to the ankle. Paragon 28's CEO, Albert DaCosta commented, “Since the inception of Paragon 28, the development of a syndesmotic stabilization system

Paragon 28 Launches R3ACT™ Stabilization System for Ankle Injuries

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-6205) for domestic ca

Paragon 28 To Report First Quarter 2022 Financial Results on May 9, 2022, and Present at the 2022 Bank of America Healthcare Conference on May 10, 2022

The consensus price target hints at a 63.3% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Paragon 28, Inc. (FNA) Climb 63% to Reach the Level Wall Street Analysts Expect?

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president

Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

Paragon 28, Inc. (FNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Paragon 28, Inc. (FNA) Upgraded to Buy: Here's Why

Here is how Paragon 28, Inc. (FNA) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Has Paragon 28, Inc. (FNA) Outpaced Other Medical Stocks This Year?

The consensus price target hints at a 63.7% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Paragon 28, Inc. (FNA) Could Surge 64%: Read This Before Placing a Bet

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting at the Canaccord Genuity Musculoskeletal Conference on March 22nd and 2022 Needham Healthcare Conference on April 11th. The Canaccord Genuity fireside chat will be webcast live on March 22, 2022, at 12:30pm ET / 9:30am PT. The Needham fireside

Paragon 28 to Present at Upcoming Canaccord Genuity Musculoskeletal Conference and Needham Healthcare Conference

Investors liked the company's 2022 revenue guidance.

Why Paragon 28 Stock Jumped Today

Paragon 28, Inc. (FNA) CEO Rob Bearden on Q4 2021 Results - Earnings Call Transcript

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and twelve months ended December 31, 2021. 2021 Highlights Net revenue $42.8 million for the fourth quarter of 2021, representing 22% growth over the fourth quarter of 2020, driven by increased revenue per US surgeon and US sales force expansion, plus strong growth i

Paragon 28 Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 8, 2022. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-620

Paragon 28 to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the acquisition of Disior Oy., a leading three-dimensional analytics pre-operative planning software company based in Helsinki, Finland, focused on the complex foot and ankle anatomy. Disior will be an integral component to SMART 28™, the company's ecosystem of enabling technologies for pre-operativ

Paragon 28 Announces Acquisition of Disior

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2021. Preliminary unaudited revenue for the fourth quarter of 2021 is expected to be in a range of $42.3 to $42.7 million, reflecting growth of 20.7% to 21.8% compared to revenue of $35.1 million for

Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its R3ACT™ Stabilization System. The R3ACT™ Stabilization System, expected to commercially launch in early 2022, will complement Paragon 28's comprehensive ankle fracture and soft tissue portfolio and further expands Parago

Paragon 28, Inc. R3ACT™ Stabilization System Cleared by FDA

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will virtually present at the 24th Annual Needham Growth Conference on Monday, January 10th. The presentation will be webcast live on Monday, January 10, 2022, at 2:45pm ET / 12:45pm MT. The webcast, as well as the archived recording, will be availa

Paragon 28 to Present at 24th Annual Needham Growth Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) announced today that it has received a supplemental approval order from the U.S. Food and Drug Administration ("FDA") for the Patient Specific Talus Spacer. The supplemental approval order allows the Patient Specific Talus Spacer to be additively manufactured in titanium alloy with a titanium nitride coating. The Patient Specific Talus Spacer was first approved on February 17, 2021, by the FDA under a Humanitarian Device Exemption

Paragon 28's Patient Specific Titanium Talus Spacer Has Been Approved by the U.S. Food and Drug Administration

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of B. Kristine Johnson and Kristina Wright to the Board of Directors, effective December 1, 2021. “I am very pleased to welcome Kris Johnson to our board of directors, as she brings a breadth of med-tech industry leadership and commercial strategy expertise. Kris' expertise in growing medical de

News for Paragon 28 Stock (FNA)